基于III期随机试验结果预测新上市药物在临床实践中的治疗效果
该研究利用RE-LY试验数据建立比例风险模型,预测达比加群vs华法林在Medicare房颤人群中卒中/体循环栓塞、大出血和全因死亡的效果。早期Medicare人群平均年龄79岁、CHADS2评分2.15,预测RR=0.73(95%CI 0.65-0.82),RD=-0.92%(-1.26%至-0.59%),与试验结果相似。基于结局模型的预测有助于在新药上市初期估计不同目标人群的平均治疗效果。
要点
- RE-LY试验中达比加群vs华法林卒中/SE的RR=0.63,预测Medicare人群RR=0.73,获益方向一致。
- Medicare早期人群平均年龄79岁高于试验的71岁,但预测的大出血和全因死亡风险与试验相似。
- 结局模型预测可在观察数据稀缺的新药上市初期为支付方覆盖决策提供依据。
核心结论
- 基于III期试验数据建立的结局模型可预测新药在不同目标人群中的平均治疗效果,预测结果与试验结果方向一致。
研究设计与样本
- 利用RE-LY试验数据拟合比例风险模型,预测2010-2011年(早期)和2010-2017年(扩展)启动达比加群或华法林的试验合格Medicare受益人2年卒中/SE、大出血和全因死亡的RR和RD。
主要发现
- 试验与早期Medicare人群平均CHADS2评分相似(2.15 vs 2.15),但平均年龄不同(71 vs 79岁)。
- 早期Medicare人群达比加群vs华法林卒中/SE的预测RR=0.73(95%CI 0.65-0.82),RD=-0.92%(-1.26%至-0.59%);试验RR=0.63(95%CI 0.50-0.76),RD=-1.37%(-1.96%至-0.77%)。
- 早期Medicare人群大出血和全因死亡风险与RE-LY试验相似,时间扩展目标人群结果相似。
临床怎么用
- 在新药上市初期观察性数据稀缺时,可利用III期试验数据建立的结局模型预测目标人群的治疗效果,辅助支付方覆盖决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Trial results may not be generalizable to target populations treated in clinical practice with different distributions of baseline characteristics that modify the treatment effect. We used outcome models developed with trial data to predict treatment effects in Medicare populations. We used data from the Randomized Evaluation of Long-Term Anticoagulation Therapy trial (RE-LY), which investigated the effect of dabigatran vs. warfarin on stroke or systemic embolism (stroke/SE) among patients with atrial fibrillation. We developed outcome models by fitting proportional hazards models in trial data. Target populations were trial-eligible Medicare beneficiaries who initiated dabigatran or warfarin in 2010-2011 ("early") and 2010-2017 ("extended"). We predicted 2-year risk ratios (RRs) and risk differences (RDs) for stroke/SE, major bleeding, and all-cause death in the Medicare populations using the observed baseline characteristics. The trial and early target populations had similar mean (SD) CHADS2 scores (2.15 (SD 1.13) vs. 2.15 (SD 0.91)) but different mean ages (71 vs. 79 years). Compared with RE-LY, the early Medicare population had similar predicted benefit of dabigatran vs. warfarin for stroke/SE (trial RR = 0.63, 95% confidence interval (CI) = 0.50 to 0.76 and RD = -1.37%, -1.96% to -0.77%, Medicare RR = 0.73, 0.65 to 0.82 and RD = -0.92%, -1.26% to -0.59%) and risks for major bleeding and all-cause death. The time-extended target population showed similar results. Outcome model-based prediction facilitates estimating the average treatment effects of a drug in different target populations when treatment and outcome data are unreliable or unavailable. The predicted effects may inform payers' coverage decisions for patients, especially shortly after a drug's launch when observational data are scarce.
引用
- Shin H, Wang SV, Kim DH, et al. Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results. Clin Pharmacol Ther. 2023. PMID: 37365904. doi:10.1002/cpt.2983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。